Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer
Name:
_Manuscript_tBRCA_LR_v5.docx
Size:
140.0Kb
Format:
Microsoft Word 2007
Description:
Identified with Open Access button
Authors
Morgan, Robert DavidBurghel, G. J.
Flaum, Nicola
Bulman, M.
Smith, P.
Clamp, Andrew R
Hasan, Jurjees
Mitchell, Claire L
Salih, Zena|Woodward, E. R.
Lalloo, F.
Shaw, J.
Desai, Sudha
Crosbie, E. J.
Edmondson, R. J.
Schlecht, H.
Wallace, A. J.
Jayson, Gordon C
Evans, D. G. R.
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2022
Metadata
Show full item recordAbstract
Aims: Clinical guidelines recommend testing both germline and tumour DNA for BRCA1/2 pathogenic variants (PVs) in non-mucinous high-grade epithelial ovarian cancer (NMEOC). In this study, we show that some tumour BRCA1/2 PVs are highly likely to be somatic based on certain clinical and variant characteristics, meaning it may not be necessary to test all NMEOC cases for germline BRCA1/2 PVs. Methods: An observational study that included all tumour BRCA1/2 PVs detected in cases of NMEOC in the Northwest of England between July 2017 and February 2022. All tumour BRCA1/2 PVs were compared with PVs recorded in a prospectively gathered pan-cancer germline BRCA1/2 (gBRCA) testing database for the same geographical region (gBRCA1 PVs=910 and gBRCA2 PVs=922). Tumour BRCA1/2 PVs were categorised as common (≥1%), uncommon (<1%) or absent from the germline database. Results: One hundred and thirteen tumour BRCA1/2 PVs were detected in 111 NMEOC cases. There were 69 germline and 44 somatic variants. The mean age at diagnosis for gBRCA and somatic BRCA1/2 (sBRCA) PVs was 56.9 and 68.5 years, respectively (Student's t-test p<0.0001). All sBRCA PVs were detected in non-familial cases. All tumour BRCA1/2 PVs with a variant allele frequency (VAF) <35% in non-familial cases were somatic variants. Eighty-one per cent of germline-tumour BRCA1/2 PVs were present (common=31, uncommon=25) in the gBRCA testing database, while 89% of somatic-tumour BRCA1/2 PVs were absent (n=39). Conclusions: We predict the likelihood of a tumour BRCA1/2 PV being somatic is 99.8% in non-familial cases of NMEOC diagnosed aged ≥75, where the VAF is ≤30% and there is no regional germline commonality.Citation
Morgan RD, Burghel GJ, Flaum N, Bulman M, Smith P, Clamp AR, et al. Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer. Journal of Clinical Pathology. BMJ; 2022.Journal
Journal of Clinical PathologyDOI
10.1136/jcp-2022-208369PubMed ID
35738887Additional Links
https://dx.doi.org/10.1136/jcp-2022-208369Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/jcp-2022-208369